Compare GCBC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GCBC | CTNM |
|---|---|---|
| Founded | 1889 | 2009 |
| Country | United States | United States |
| Employees | 227 | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.1M | 550.7M |
| IPO Year | 1998 | 2024 |
| Metric | GCBC | CTNM |
|---|---|---|
| Price | $35.47 | $10.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $21.43 |
| AVG Volume (30 Days) | 18.8K | ★ 659.1K |
| Earning Date | 10-22-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ 31.69 | 0.46 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.75 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $21.38 | $6.73 |
| 52 Week High | $37.25 | $17.79 |
| Indicator | GCBC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 50.10 |
| Support Level | $33.55 | $8.59 |
| Resistance Level | $35.84 | $13.72 |
| Average True Range (ATR) | 0.92 | 0.81 |
| MACD | -0.12 | 0.30 |
| Stochastic Oscillator | 10.48 | 71.40 |
Greene Bancorp Inc is the holding company. Through its subsidiaries, the company operates as a provider of community-based banking services throughout the Hudson Valley and Capital Region of New York State. Its customers include individuals, businesses, municipalities and other institutions.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.